Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

by M. Ruiz-Borrego, A. Chan, G. Marx, A. Brufsky, M. Trudeau, D. Egle, L. McCulloch, D. Tripathy, C.H. Barcenas
Published 2021-04-01

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

by I. Blancas, C. Olier, V. Conde, J. L. Bayo, C. Herrero, I. Zarcos-Pedrinaci, F. Carabantes, J. M. Baena-Cañada, J. Cruz, M. Ruiz-Borrego
Published 2021-02-01

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

by A. Barnadas, M. Muñoz, M. Margelí, J. I. Chacón, J. Cassinello, S. Antolin, E. Adrover, M. Ramos, E. Carrasco, M. A. Jimeno, B. Ojeda, X. González, S. González, M. Constenla, J. Florián, A. Miguel, A. Llombart, A. Lluch, M. Ruiz-Borrego, R. Colomer, S. Del Barco, On behalf of GEICAM, Spanish Breast Cancer Group
Published 2019-12-01

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

by A. C. Picornell, I. Echavarria, E. Alvarez, S. López-Tarruella, Y. Jerez, K. Hoadley, J. S. Parker, M. del Monte-Millán, R. Ramos-Medina, J. Gayarre, I. Ocaña, M. Cebollero, T. Massarrah, F. Moreno, J. A. García Saenz, H. Gómez Moreno, A. Ballesteros, M. Ruiz Borrego, C. M. Perou, M. Martin
Published 2019-06-01